| Starch and sucrose metabolism |
1.82 |
1.16e-1 |
25/36 (69.44%) |
MGAM;HK2;GBA3;...
|
| Carbohydrate digestion and absorption |
1.79 |
1.05e-1 |
37/47 (78.72%) |
MGAM;SLC37A4;PRKCB;...
|
| Tryptophan metabolism |
1.74 |
1.09e-1 |
35/42 (83.33%) |
ACAT1;AOC1;ALDH2;...
|
| Arginine and proline metabolism |
1.73 |
8.69e-2 |
39/50 (78%) |
AOC1;ALDH2;ODC1;...
|
| Renin-angiotensin system |
1.70 |
9.06e-2 |
20/23 (86.96%) |
ANPEP;CTSG;CPA3;...
|
| Folate biosynthesis |
1.69 |
8.25e-2 |
23/26 (88.46%) |
AKR1C3;QDPR;CBR1;...
|
| Glyoxylate and dicarboxylate metabolism |
1.67 |
9.18e-2 |
23/30 (76.67%) |
ACAT1;SHMT1;CS;...
|
| Cell cycle |
1.64 |
9.88e-2 |
110/124 (88.71%) |
CDC25A;CDC20;YWHAH;...
|
| Glycolysis / Gluconeogenesis |
1.63 |
9.48e-2 |
56/67 (83.58%) |
ALDH2;PGAM1;PFKP;...
|
| Fc epsilon RI signaling pathway |
1.59 |
1.38e-1 |
57/68 (83.82%) |
ALOX5;ALOX5AP;FCER1G;...
|
| Fructose and mannose metabolism |
1.57 |
1.39e-1 |
30/33 (90.91%) |
PFKP;HK2;AKR1B10;...
|
| Central carbon metabolism in cancer |
1.57 |
1.35e-1 |
67/70 (95.71%) |
PGAM1;G6PD;PFKP;...
|
| Neomycin, kanamycin and gentamicin biosynthesis |
1.53 |
1.90e-1 |
5/5 (100%) |
HK2;HK3
|
| Oocyte meiosis |
1.52 |
1.89e-1 |
90/129 (69.77%) |
CDC20;YWHAH;PLK1;...
|
| Galactose metabolism |
1.50 |
2.03e-1 |
26/31 (83.87%) |
MGAM;PFKP;HK2;...
|
| Pyruvate metabolism |
1.50 |
2.00e-1 |
41/47 (87.23%) |
ACAT1;ALDH2;DLAT;...
|
| B cell receptor signaling pathway |
1.48 |
2.14e-1 |
71/81 (87.65%) |
PRKCB;NFATC3;CD22;...
|
| Neutrophil extracellular trap formation |
1.45 |
2.75e-1 |
101/189 (53.44%) |
CAMP;AZU1;ELANE;...
|
| Histidine metabolism |
1.43 |
3.04e-1 |
16/22 (72.73%) |
AOC1;ALDH2;ASPA;...
|
| Nitrogen metabolism |
1.42 |
3.23e-1 |
16/17 (94.12%) |
CA12;CA2;CA3;...
|
| Long-term depression |
1.42 |
3.11e-1 |
55/60 (91.67%) |
PRKCB;GNA11;GUCY1A1;...
|
| Protein digestion and absorption |
1.39 |
3.62e-1 |
78/103 (75.73%) |
SLC3A1;SLC1A1;COL4A5;...
|
| Pentose phosphate pathway |
1.39 |
3.47e-1 |
25/30 (83.33%) |
G6PD;PFKP;TKTL1;...
|
| Gastric acid secretion |
1.39 |
3.38e-1 |
63/76 (82.89%) |
CA2;SST;PRKCB;...
|
| Fatty acid degradation |
1.39 |
3.30e-1 |
40/43 (93.02%) |
ACAT1;ALDH2;ACSL1;...
|
| Citrate cycle (TCA cycle) |
1.39 |
3.22e-1 |
30/30 (100%) |
CS;DLST;DLAT;...
|
| TGF-beta signaling pathway |
1.36 |
3.58e-1 |
81/94 (86.17%) |
TGFB1;PPP2R1B;PPP2CB;...
|
| Aldosterone-regulated sodium reabsorption |
1.33 |
3.99e-1 |
34/37 (91.89%) |
PRKCB;HSD11B2;FXYD2;...
|
| Glutathione metabolism |
1.32 |
3.98e-1 |
43/57 (75.44%) |
ANPEP;ODC1;G6PD;...
|
| Leishmaniasis |
1.32 |
3.98e-1 |
67/77 (87.01%) |
ITGAM;EEF1A2;TGFB1;...
|
| Type I diabetes mellitus |
-1.28 |
4.56e-1 |
38/43 (88.37%) |
FAS;CD86;HSPD1;...
|
| Small cell lung cancer |
-1.28 |
4.65e-1 |
90/92 (97.83%) |
BIRC7;LAMA3;LAMB2;...
|
| Transcriptional misregulation in cancer |
-1.29 |
4.67e-1 |
158/192 (82.29%) |
RELA;NGFR;BMI1;...
|
| Human papillomavirus infection |
-1.30 |
4.54e-1 |
284/331 (85.8%) |
HDAC1;LAMA3;LAMB2;...
|
| ECM-receptor interaction |
-1.32 |
4.07e-1 |
80/88 (90.91%) |
DAG1;RELN;LAMC3;...
|
| Viral carcinogenesis |
-1.33 |
3.99e-1 |
149/203 (73.4%) |
SRF;STAT3;HDAC3;...
|
| Antigen processing and presentation |
-1.33 |
4.07e-1 |
60/78 (76.92%) |
HLA-A;PDIA3;HLA-E;...
|
| Endometrial cancer |
-1.34 |
3.89e-1 |
56/58 (96.55%) |
ILK;CDH1;CTNNA1;...
|
| Epstein-Barr virus infection |
-1.35 |
3.80e-1 |
189/202 (93.56%) |
STAT3;ICAM1;CD247;...
|
| Breast cancer |
-1.36 |
3.80e-1 |
119/147 (80.95%) |
FRAT1;CTNNB1;WNT7A;...
|
| Arrhythmogenic right ventricular cardiomyopathy |
-1.38 |
3.55e-1 |
70/77 (90.91%) |
CACNA2D2;ITGA5;ITGB3;...
|
| Phosphonate and phosphinate metabolism |
-1.39 |
3.32e-1 |
5/6 (83.33%) |
CHPT1;CEPT1
|
| Cholesterol metabolism |
-1.43 |
2.47e-1 |
44/50 (88%) |
ABCG5;CYP7A1;APOA2;...
|
| Lysosome |
-1.44 |
2.60e-1 |
115/128 (89.84%) |
CTSS;TPP1;LAMP3;...
|
| Toll-like receptor signaling pathway |
-1.45 |
2.44e-1 |
94/104 (90.38%) |
IFNAR2;SPP1;IRF3;...
|
| Apoptosis |
-1.45 |
2.54e-1 |
126/168 (75%) |
NGF;RELA;NGFR;...
|
| Kaposi sarcoma-associated herpesvirus infection |
-1.49 |
2.08e-1 |
172/193 (89.12%) |
GABARAPL2;STAT3;ICAM1;...
|
| Graft-versus-host disease |
-1.50 |
2.07e-1 |
32/42 (76.19%) |
FAS;CD86;HLA-A;...
|
| Complement and coagulation cascades |
-1.50 |
2.14e-1 |
76/85 (89.41%) |
SERPINE1;FGA;PROS1;...
|
| Protein processing in endoplasmic reticulum |
-1.52 |
1.97e-1 |
127/171 (74.27%) |
ATF4;PDIA6;SAR1A;...
|
| PPAR signaling pathway |
-1.52 |
2.17e-1 |
66/74 (89.19%) |
CYP7A1;APOA2;ACOX3;...
|
| Allograft rejection |
-1.53 |
2.25e-1 |
32/38 (84.21%) |
FAS;CD86;HLA-A;...
|
| Various types of N-glycan biosynthesis |
-1.54 |
2.41e-1 |
26/39 (66.67%) |
DDOST;RPN2;STT3A;...
|
| Cytosolic DNA-sensing pathway |
-1.57 |
2.21e-1 |
52/63 (82.54%) |
RELA;NFKBIB;IL33;...
|
| Autoimmune thyroid disease |
-1.60 |
1.71e-1 |
46/53 (86.79%) |
FAS;CD86;TSHR;...
|
| Other glycan degradation |
-1.62 |
1.81e-1 |
13/18 (72.22%) |
NEU1;MAN2C1;MAN2B1;...
|
| Basal cell carcinoma |
-1.68 |
1.34e-1 |
41/63 (65.08%) |
CTNNB1;WNT7A;CDKN1A;...
|
| Primary bile acid biosynthesis |
-1.72 |
1.13e-1 |
15/17 (88.24%) |
AKR1C4;CYP7A1;SLC27A5;...
|
| Thyroid cancer |
-1.75 |
1.46e-1 |
36/37 (97.3%) |
CTNNB1;RXRG;CDKN1A;...
|
| Viral myocarditis |
-1.77 |
1.88e-1 |
53/60 (88.33%) |
ABL2;RAC1;HLA-A;...
|
